137 related articles for article (PubMed ID: 30218601)
21. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
22. [Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer].
Jiang L; Lu YP
Zhonghua Nan Ke Xue; 2015 Jul; 21(7):655-8. PubMed ID: 26333230
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review.
Pecoraro V; Roli L; Plebani M; Trenti T
Clin Chem Lab Med; 2016 Jul; 54(7):1123-32. PubMed ID: 26609863
[TBL] [Abstract][Full Text] [Related]
24. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
25. The prostate health index selectively identifies clinically significant prostate cancer.
Loeb S; Sanda MG; Broyles DL; Shin SS; Bangma CH; Wei JT; Partin AW; Klee GG; Slawin KM; Marks LS; van Schaik RH; Chan DW; Sokoll LJ; Cruz AB; Mizrahi IA; Catalona WJ
J Urol; 2015 Apr; 193(4):1163-9. PubMed ID: 25463993
[TBL] [Abstract][Full Text] [Related]
26. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
28. Stability and accuracy of total and free PSA values in samples stored at room temperature.
Forde JC; Blake O; Crowley VE; Lynch TH
Ir J Med Sci; 2016 Nov; 185(4):989-991. PubMed ID: 26443748
[TBL] [Abstract][Full Text] [Related]
29. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
30. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples.
Piironen T; Pettersson K; Suonpää M; Stenman UH; Oesterling JE; Lövgren T; Lilja H
Urology; 1996 Dec; 48(6A Suppl):81-7. PubMed ID: 8973706
[TBL] [Abstract][Full Text] [Related]
31. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
[TBL] [Abstract][Full Text] [Related]
32. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
33. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
34. The stability of free and bound prostate-specific antigen.
Cartledge JJ; Thompson D; Verril H; Clarkson P; Eardley I
BJU Int; 1999 Nov; 84(7):810-4. PubMed ID: 10532977
[TBL] [Abstract][Full Text] [Related]
35. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
36. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
37. Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.
Schlack K; Krabbe LM; Fobker M; Schrader AJ; Semjonow A; Boegemann M
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618028
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
[TBL] [Abstract][Full Text] [Related]
39. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
40. Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions.
Igawa T; Takehara K; Onita T; Ito K; Sakai H
J Clin Lab Anal; 2014 Jul; 28(4):315-9. PubMed ID: 24578247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
